Chemomab Therapeutics Ltd.

4.10+0.2600+6.77%Vol 102.90K1Y Perf -82.17%
Jun 24th, 2022 15:59 DELAYED
BID4.01 ASK4.15
Open3.75 Previous Close3.84
Pre-Market- After-Market-
 - -  - -%
Target Price
22.00 
Analyst Rating
Strong Buy 1.00
Potential %
436.59 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
7.30 
Earnings Rating
Market Cap46.76M 
Earnings Date
12th Aug 2022
Alpha-0.08 Standard Deviation0.23
Beta1.16 

Today's Price Range

3.754.14

52W Range

2.5324.04

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
23.49%
1 Month
41.87%
3 Months
-17.67%
6 Months
-45.62%
1 Year
-82.17%
3 Years
-93.97%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CMMB4.100.26006.77
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.40-0.44-10.00
Q04 2021-0.40-0.44-10.00
Q03 2021-0.02-0.26-1 200.00
Q02 2021-0.02-0.26-1 200.00
Q01 2021-0.43-0.2248.84
Q04 2020-8.00-4.0050.00
Q03 2020-7.20-5.6022.22
Q02 2020-8.80-7.2018.18
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date12th Aug 2022
Estimated EPS Next Report-0.60
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume102.90K
Shares Outstanding11.40K
Shares Float11.39M
Trades Count345
Dollar Volume411.82K
Avg. Volume52.60K
Avg. Weekly Volume78.35K
Avg. Monthly Volume43.67K
Avg. Quarterly Volume35.79K

Chemomab Therapeutics Ltd. (NASDAQ: CMMB) stock closed at 4.1 per share at the end of the most recent trading day (a 6.77% change compared to the prior day closing price) with a volume of 102.90K shares and market capitalization of 46.76M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 0 people. Chemomab Therapeutics Ltd. CEO is Dale R. Pfost.

The one-year performance of Chemomab Therapeutics Ltd. stock is -82.17%, while year-to-date (YTD) performance is -40.58%. CMMB stock has a five-year performance of %. Its 52-week range is between 2.53 and 24.0399, which gives CMMB stock a 52-week price range ratio of 7.30%

Chemomab Therapeutics Ltd. currently has a PE ratio of -2.40, a price-to-book (PB) ratio of 0.66, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -26.97%, a ROC of -28.07% and a ROE of -29.05%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Chemomab Therapeutics Ltd., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.60 for the next earnings report. Chemomab Therapeutics Ltd.’s next earnings report date is 12th Aug 2022.

The consensus rating of Wall Street analysts for Chemomab Therapeutics Ltd. is Strong Buy (1), with a target price of $22, which is +436.59% compared to the current price. The earnings rating for Chemomab Therapeutics Ltd. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Chemomab Therapeutics Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Chemomab Therapeutics Ltd. has a Neutral technical analysis rating based on Technical Indicators (ADX : 37.44, ATR14 : 0.39, CCI20 : 135.48, Chaikin Money Flow : 0.31, MACD : 0.13, Money Flow Index : 88.06, ROC : -1.20, RSI : 64.84, STOCH (14,3) : 83.85, STOCH RSI : 1.00, UO : 60.14, Williams %R : -16.15), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Chemomab Therapeutics Ltd. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet need. The company's lead candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.

CEO: Dale R. Pfost

Telephone: +972 773310156

Address: Kiryat Atidim, Tel Aviv 6158002, , IL

Number of employees: 0

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

47%53%

Bearish Bullish

52%48%

Bearish Bullish

56%44%

News

Stocktwits